中药注射液联合GP方案治疗非小细胞肺癌的多维贝叶斯网络Meta分析
该研究通过多维贝叶斯网络Meta分析比较不同中药注射液联合吉西他滨+顺铂(GP)方案治疗非小细胞肺癌的疗效与安全性,纳入71项RCT和10种中药注射液。结果显示联合治疗优于单纯GP,其中得力生注射液在临床有效率(94.60%)、康艾注射液在胃肠道反应(82.62%)、复方苦参注射液在体力状况(73.36%)和肝功能异常(87.17%)、参麦注射液在白细胞减少(94.59%)和血小板减少(99.18%)概率最高。
要点
- 中药注射液联合GP方案在NSCLC患者中疗效与安全性优于单纯GP。
- 得力生和康艾注射液在临床有效率和胃肠道反应方面概率最高。
- 复方苦参、参麦注射液分别在体力状况和血液学毒性方面概率最高。
核心结论
- 中药注射液联合GP方案对NSCLC患者的疗效和安全性优于单纯GP方案。
研究设计与样本
- 研究为多维贝叶斯网络Meta分析,纳入71项随机对照试验(RCT)和10种中药注射液。
- 检索7个电子数据库,截止2020年4月30日,采用Stata 13.0、WinBUGS 14.0和R 3.6.1进行数据分析。
主要发现
- 得力生注射液联合GP的临床有效率概率最高(94.60%)。
- 康艾注射液联合GP的胃肠道反应概率最高(82.62%)。
- 复方苦参注射液联合GP在体力状况(73.36%)和肝功能异常(87.17%)概率最高。
- 参麦注射液联合GP在白细胞减少(94.59%)和血小板减少(99.18%)概率最高。
临床怎么用
- 临床可考虑将中药注射液联合GP方案用于NSCLC患者,以改善疗效和安全性。
- 根据患者具体情况,如关注临床有效率可优先考虑得力生注射液,关注胃肠道反应可考虑康艾注射液。
- 对于体力状况和肝功能异常,可关注复方苦参注射液;对于血液学毒性,可关注参麦注射液。
局限性
- 本网络Meta分析存在局限性,需进一步设计良好、大样本、多中心的RCT来充分支持结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: As non-small cell lung cancer (NSCLC) seriously threatens human health, several clinical studies have reported that Chinese herbal injections (CHIs) in combination with and gemcitabine plus cisplatin (GP) are beneficial. This multidimensional network meta-analysis aimed to compare the clinical efficacy and safety of different CHIs in combination with GP against NSCLC. Methods: Randomized controlled trials (RCTs) for the treatment of NSCLC were retrieved from seven electronic databases from inception to April 30, 2020. Study selection and data extraction were based on a priori criteria. Data analysis was performed using Stata 13.0, WinBUGS 14.0 software. Multidimensional cluster analysis was performed using the "scatterplot3d" package in R 3.6.1 software. Results: This network meta-analysis included 71 eligible RCTs and 10 Chinese herbal injections. Delisheng injection and Kangai injection had the highest probability in terms of clinical effectiveness rate (94.60%) and gastrointestinal reactions (82.62%) when combined with GP compared with the other interventions. Compound Kushen injection combined with GP ranked ahead of the other interventions in terms of performance status (73.36%) and abnormal liver function (87.17%). Shenmai injection combined with GP had the highest probability in terms of leukopenia (94.59%) and thrombocytopenia (99.18%). Conclusion: The current evidence revealed that CHIs combined with GP have a better impact on patients with NSCLC than GP alone. Aidi injection, Compound kushen injection, and Kanglaite injection deserve more attention of clinicians when combined with GP in patients with NSCLC. Additionally, due to the limitations of this network meta-analysis, further well-designed, large-sample, multicenter RCTs are required to support our findings adequately.
引用
- Ni M, Wu Z, Wang H, et al. A Multidimensional Bayesian Network Meta-Analysis of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Gemcitabine and Cisplatin. Front Pharmacol. 2021. PMID: 34552496. doi:10.3389/fphar.2021.739673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。